RecruitingNCT05991193

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

A Non-interventional Study and Its Clinical Relevance With Central Nervous System Metastatic Epidermal Growth Factor Receptor Mutation Positive Non-small Cell Lung Cancer


Sponsor

Hunan Province Tumor Hospital

Enrollment

100 participants

Start Date

Dec 29, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patients must be ≥18 years.
  • Provision of fully informed consent prior to any study specific procedures.
  • Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically. The mutations above may exist alone or together.
  • Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC).
  • According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.

Exclusion Criteria1

  • None

Locations(1)

Hunan Cancer hospital

Changsha, Hunan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05991193


Related Trials